AOD-9604safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for AOD-9604 as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. AOD-9604 is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

AOD-9604 has a relatively well-characterised short-term human safety profile by the standards of research peptides, owing to its passage through formal Phase I and Phase IIb clinical trials. In Phase I studies, single doses up to 1 mg/kg intravenously and repeated daily subcutaneous doses over 12 weeks were generally well tolerated. There were no clinically significant effects on IGF-1, glucose tolerance, insulin sensitivity, lipid profiles, thyroid function, or cortisol — the hormonal safety parameters of most concern when manipulating the GH axis. No serious adverse events were attributed to the peptide in published trial reports. At the site of subcutaneous injection, mild transient reactions including erythema, induration, and pruritus were reported in a minority of subjects. Systemic adverse events did not differ significantly from placebo in controlled periods. The most important safety caveat for ongoing research is the absence of long-term human data beyond 12–16 weeks of continuous administration. Potential effects of sustained β3-AR sensitisation on cardiac tissue (where β3-AR is also expressed and modulates contractility) have not been characterised in the context of AOD-9604. Immunogenicity studies for anti-peptide antibody induction over longer periods have not been published. For intra-articular research use, the safety considerations of the joint-injection procedure itself — sterility, volume, and carrier — are as important as any peptide-specific toxicology. Human intra-articular AOD-9604 data are extremely limited.

UK regulatory status

AOD-9604 is not licensed for any therapeutic indication by the UK Medicines and Healthcare products Regulatory Agency (MHRA). It has not received marketing authorisation in the UK, EU, or United States. Australia's TGA classification as a 'novel food ingredient' in 2014 is specific to Australian food-standards legislation and does not confer any regulatory status in the United Kingdom. The WADA position on AOD-9604 has been complex. The compound is not listed by its specific name on the annual WADA Prohibited List in the same way that established substances appear, but WADA's broader category S2 ('Peptide hormones, growth factors, related substances and mimetics') could be interpreted to encompass growth hormone fragments and analogues. Anti-doping proceedings following the Essendon AFL controversy involved consideration of whether AOD-9604 fell within WADA's scope; outcomes varied across different proceedings. Athletes and researchers associated with competitive sport should consult the current WADA Prohibited List and seek specific legal advice on AOD-9604's status. Research-laboratory possession of AOD-9604 in the UK is unrestricted. It is not a controlled drug under the Misuse of Drugs Act 1971. Clinical or therapeutic administration to humans without MHRA authorisation is not permitted. No MHRA enforcement actions against AOD-9604 specifically have been publicly disclosed.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. AOD-9604 is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full AOD-9604 research context including mechanism, study citations, and references, see the main AOD-9604 research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.